
Findings from the phase 3 PANOVA-3 trial showed that adding tumor treating fields to gemcitabine and nab-paclitaxel prolonged time to quality-of-life deterioration and improved pain outcomes in unresectable, locally advanced pancreatic cancer.
Clinical Approach for Platinum-Sensitive Recurrent Ovarian Cancer
Platinum-Sensitive Recurrent Ovarian Cancer
September 2014
November 2016
January 2018






